You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
《大行報告》中金:國家醫保支持中醫 中成藥看好白雲山、同仁堂科技等 中藥飲片看好中國中藥
中金髮表報告指,去年12月30日國家醫療保障局、國家中醫藥管理局發佈《國家醫療保障局國家中醫藥管理局關於醫保支持中醫藥傳承創新發展的指導意見》,充分發揮醫療保障制度優勢,支持中醫藥傳承創新發展 。 當中提出,中藥製劑、互聯網中醫藥服務、中醫適宜技術等納入醫保範圍,並推進中醫醫保支付方式改革,中醫醫療機構暫不實行DRG付費。而中藥飲片銷售順加不超25%,鼓勵配方顆粒進各地集採。 中金指,截至去年12月30日,中藥板塊2022年市盈率爲25.8倍,生物醫藥板塊2022年市盈率爲29.8倍。該行認爲內地政策鼓勵中醫藥發展明顯,相對於生物醫藥板塊整體,中藥板塊估值中樞存在溢價空間。 建議關注中成藥,包括具品牌優勢的華潤三九(000999.SZ)、白雲山(00874.HK)、同仁堂(600085.SH)、同仁堂科技(01666.HK)、同仁堂國藥(03613.HK)、東阿阿膠(000423.SZ)及片仔(黃)(600436.SH),中藥飲片建議關注中國中藥(00570.HK),中醫服務建議關注京東健康(06618.HK)、阿裏健康(00241.HK)。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account